1	Small RNA sequencing reveals snoRNAs and piRNA-019825 as novel players in diabetic kidney
2	disease
3	
4	LM 't Hart ^{1,2,3,4} (ORCID 0000-0003-4401-2938), JA de Klerk ^{1,5,6} , GA Bouland ¹ , JHD Peerlings ¹ , M.T.
5	Blom ^{3,7} , SJ Cramer ¹ , R Bijkerk ^{5,6} , JWJ Beulens ^{2,3} , RC Slieker ¹
6	
7	¹ Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The
8	Netherlands
9	² Department of Epidemiology and Data Sciences, Amsterdam University Medical Center, Location
10	Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
11	³ Health Behaviors & Chronic Diseases Research Program & Personalised Medicine Research
12	Program, Amsterdam Public Health, Amsterdam, The Netherlands
13	⁴ Department of Biomedical Data Sciences, Section Molecular Epidemiology, Leiden University
14	Medical Center, Leiden, The Netherlands
15	⁵ Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center,
16	Leiden, The Netherlands
17	⁶ Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center,
18	Leiden, The Netherlands
19	⁷ Department of General Practice, Amsterdam University Medical Center, Location Vrije Universiteit
20	Amsterdam, Amsterdam, The Netherlands
21	
22	Author for correspondence:
23	LM 't Hart, PhD
24	Leiden University Medical Center
25	Department of Cell and Chemical Biology
26	Albinusdreef 2
27	2333ZA Leiden, The Netherlands
28	+31 715269796
29	lmthart@lumc.nl
30	
31	

32 Abstract

- **Introduction** Micro- and macrovascular complications are common among persons with type 2
- 34 diabetes. Recently there has been growing interest to investigate the potential of circulating small non-
- coding RNAs (sncRNAs) as contributors to the development of diabetic complications. In this study
- 36 we investigate to what extent circulating sncRNAs levels associate with prevalent diabetic kidney
- 37 disease (DKD) in persons with type 2 diabetes.
- 38 Methods Plasma sncRNAs levels were determined using small RNA-seq, allowing detection of
- 39 miRNAs, snoRNAs, piRNAs, tRNA-fragments and various other sncRNA classes. We tested for
- 40 differentially expressed sncRNAs in persons with type 2 diabetes, with DKD (n=69) or without DKD
- 41 (n=405). In secondary analyses, we also tested the association with eGFR, albuminuria (UACR) and
- 42 the plasma proteome.
- 43 **Results** In total seven sncRNAs were negatively associated with prevalent DKD (all $P_{FDR} \le 0.05$).
- 44 Including one microRNA (miR-143-5p), five snoRNAs (U8, SNORD118, SNORD24, SNORD107,
- 45 SNORD87) and a piRNA (piR-019825|DQ597218). Proteomic analyses showed that the seven
- sncRNAs, and especially the piRNA piR-019825, were associated with plasma levels of 24 proteins of
- 47 which several have known associations with kidney function including TNF sR-I (TNFRFS1A), DAN
- 48 (NBL1) and cystatin C (CST3).
- 49 Conclusion We have identified novel small non-coding RNAs, primarily from classes other than
- 50 microRNAs, that are associated with diabetic kidney disease. Our results shows that the involvement
- of small non-coding RNAs in DKD goes beyond the already known microRNAs and also involves
- 52 other classes of sncRNA, in particular snoRNAs and the piRNA piR-019825, that have never been
- 53 studied before in relation to kidney function.
- 54
- 55 Keywords: Type 2 diabetes, small RNA, microRNA, snoRNA, piRNA, Chronic kidney disease,
- 56 Nephropathy
- 57

58 Introduction

59 Diabetic kidney disease (DKD) is one of the most common complications in type 2 diabetes.
60 Nonetheless, while some develop complications early in the disease, others will never. The
61 mechanisms underlying DKD are not fully understood though [1].

62 Circulating small non-coding RNAs (sncRNA) are mostly contained in extracellular vesicles 63 or are bound to RNA-binding proteins and lipoproteins and originate from various tissues including 64 tissues important in kidney function [2]. Whereas previously it was thought that sncRNAs merely 65 reflect degradation by-products, it has now been shown that they exert important functions in cell-to-66 cell communication, the regulation of gene expression, splicing and ribosomal RNA maturation [2].

Although a substantial number of studies have examined circulating sncRNAs associated with kidney function in persons with diabetes, most studies are relatively small (n<100) and focused on microRNAs. From these studies a large number of miRNAs have emerged that are putatively associated with kidney function. However, probably due to small sample sizes, heterogeneity in endpoints and methodology used there is limited consistency between studies as shown in various meta-analyses [3-5].

To the best of our knowledge there are currently no studies that have systematically examined the other classes (biotypes) of small ncRNA. We thus go beyond the current state-of-the-art by not only investigating microRNAs but also other sncRNAs classes, including besides miRNAs, piRNAs, tRNA fragments (tRFs), lncRNA fragments, Y-RNAs and snoRNAs. For this we applied small RNA sequencing in a large well-defined cohort (n=474) of persons with and without DKD to capture the whole plasma sncRNA transcriptome allowing for a hypothesis-free, comprehensive analysis of the role of sncRNAs in diabetic kidney disease [6].

80

81 Materials and Methods

A schematic overview of the study design can be found in Supplemental Figure 1.

83

84 *Study sample*

85 For this project we used data from the Hoorn Diabetes Care System cohort (DCS), a large prospective 86 study comprised of 14,000+ individuals with type 2 diabetes who receive structed diabetes care [7]. 87 Participants visit the Hoorn diabetes research center annually for diabetes care including routine 88 biochemistry, medication review and clinical care. Patients were also invited to participate in DCS 89 biobanks in which we combine the annual phenotypic data with biobanking of liquid biopsies which 90 includes serum, plasma and urine. Blood samples were collected during two phases of biobanking in 91 2008/2009 and 2012-2014. For the current study we used a subsample from the whole DCS biobank 92 (n=475) using the following inclusion criteria: a plasma sample collected within four years after 93 diagnosis of diabetes and no-insulin use at the time of blood sampling.

94 All laboratory measurements were on samples taken in a fasted state on the same day as the 95 sample for RNA-seq. Routine anthropometric, biochemistry methods and definitions have been 96 described previously in detail in van der Heijden et al. [7]. Kidney function was assessed based on 97 eGFR (CKD-EPI) and urinary albumin to creatinine ratio (UACR) and included as continuous 98 variables in our analyses. Stages of chronic kidney disease (CKD) were defined according the KDIGO 99 criteria as previously described [8]. In short, this definition uses a combination of eGFR and UACR to 100 categorize persons based on kidney function. Persons in stage 0 do not show signs of kidney 101 dysfunction whereas the stages 1 to 3 have increasing kidney dysfunction as shown in Supplemental 102 Figure 2. Cases were defined as having CKD stage > 1 (i.e. $eGFR < 60 \text{ ml/min}/1.73 \text{ m}^2$ and/or UACR 103 >3 mg/mmol) at the time of blood sampling for sncRNA analysis which resulted in 69 cases.

104

105 Circulating small RNA sequencing

106 Circulating sncRNAs were isolated from 900ul of citrate plasma using a commercial cell-free RNA 107 isolation kit (Quick-cfRNA Serum & Plasma Kit, Zymo Research, Irvine, CA, USA). After quality 108 control 475 samples were submitted for RNA sequencing. Library preps were constructed using the 109 NEBNext® Multiplex Small RNA Library Prep Set for Illumina (New England Biolabs, Ipswich, MA, 110 USA). A Pippin Prep instrument (Sage Science, Beverly, MA, USA) was used for size selection to 111 further enrich for sncRNAs with a size of ~20 to 100 nucleotides. Sequencing was performed using the 112 Illumina NextSeq500 sequencer with v2.5 sequencing reagent kits and 35 cycle paired-end reads 113 (PE35). On average 11.3±2.8 million reads per sample were generated. The exceRpt pipeline [9], 114 developed by the NIH Extracellular RNA Communication Consortium (ERCC), was used to map the 115 obtained reads, for quality control, to process the data and generate RNA abundance estimates for 116 miRNA, piRNA, lncRNA, tRNA fragments, Y_RNA (fragments), snRNA, snoRNA, scaRNA and 117 various other sncRNA species. Using respectively miRBase v22 [10], piRNABank v1 [11], Gencode 118 (version 38) [12], circBase [13] and GtRNAdb [14]. One sample did not pass the QC thresholds.

119

120 Taqman validation of the RNA-seq results

121 We used Taqman qPCR assays (ThermoFisher Scientific, NL) to verify the validity and 122 reproducibility of the small RNA-seq results. First cDNA was generated from 5ng of RNA isolated 123 from plasma using the TaqManTM Advanced miRNA cDNA Synthesis Kit (ThermoFisher Scientific, 124 NL) according to the instructions of the manufacturer. We chose four miRNA assays with a range 125 from low to relative high expression in our study sample (miR-542-3p, miR-323b-3p, miR-186-5p and 126 miR-423-5p) which were measured in 12 randomly selected plasma RNA samples for which sncRNA-127 seq data were available. Clinical characteristics are shown in Supplemental Table 1. The Taqman 128 qPCR assays were run according to the manufacturer's instructions using TaqMan Fast Advanced

129 Master mix and TaqMan Advanced miRNA Assays (ThermoFisher Scientific, NL). miR-191-5p

130 expression was used as the reference (housekeeping gene) in both the Taqman and small RNA-seq

131 datasets as suggested by the manufacturer [15].

132

133 Expression patterns of small RNAs in tissues

Publicly available raw sncRNA-seq data for various metabolic tissues were downloaded from the Gene Expression Omnibus (GEO) [16]. The tissues for which sncRNA-seq data was used included kidney, thyroid, brain, liver, muscle, heart, colon, pancreas, subcutaneous white adipose tissue and whole blood and urine. Accession numbers are given in Supplemental Table 2. Data were processed using the exceRpt pipeline as described above. The tissue data were used to estimate the abundance of the sncRNAs in these tissues. Data was z-scaled in figures.

140

141 *Plasma proteomics.*

Plasma proteomic data was available for 589 participants of the Hoorn DCS study and generated using the SomaLogic SOMAscan platform (Boulder, CO) as previously described [17]. After quality control 144 1195 protein levels were available for analysis. For 199 subjects we also had the corresponding 145 sncRNA-seq data from the same sampling date. Clinical characteristics of the participants in this study 146 are shown in Supplemental Table 1.

147

148 Statistical analysis

149 The R-package edgeR (v3.42.4) was used to identify differentially expressed sncRNAs [18]. A 150 negative binomial generalized log-linear model was applied using edgeR's function 151 *estimateGLMRobustDisp.* For the determination of differential expression and p-values we used the 152 quasi-likelihood (QL) F-test using edgeR's glmQLFTest function according to the recommendations 153 of the developers. The base model was unadjusted. A fully adjusted model was adjusted for BMI, 154 diabetes duration, HbA1c, HDL, SBP and smoking unless otherwise stated. Age and sex were 155 excluded from the model as these are part of the definition of eGFR. UACR was log10-transformed 156 before analysis. In sensitivity analyses, we additionally included use of antihypertensive medication 157 and or eGFR or UACR. The correlation between the sncRNA transcriptome and plasma proteome was 158 tested using a linear model with the log transformed proteomic measurements as outcome and the 159 sncRNA transcriptome as predictors with adjustment for age, BMI, sex and technical covariates. 160 Associations between the proteome and eGFR or UACR were tested using the same model. The 161 Benjamini-Hochberg procedure was used to adjust for multiple hypothesis testing and an FDR below 162 0.05 was considered significant.

- 163
- 164 **Results**
- 165 *Clinical characteristics*

The clinical characteristics of our study group are shown in Table 1. The characteristics resemble those of a typical T2D population with slightly more males than females, a mean age-at-diagnosis of 59.3 ± 9.0 years, BMI of 30.7 ± 6.0 kg/m2 and an average duration of diabetes at time of blood sampling of 2.2 ± 1.1 years. Glycemic control was good with an average HbA1c of 46 (42, 51) mmol/mol. Prevalence of DKD at the time of blood sampling was 15%.

171

172 sncRNA biotype abundance in our samples

173After quality control, 938 sncRNAs were expressed above the threshold of a mean \geq 5 copies174in our data, which included miRNAs, piRNA, Y_RNA fragments, lncRNA fragments,175tRNA_fragments, snoRNAs, snRNAs and various other sncRNA species (Table 2). miRNAs, Y-176RNAs and tRFs were the most abundant sncRNAs biotypes comprising respectively 57.6, 34.9 and 4.8177percent of all reads. Other sncRNA biotypes were much less abundant (\leq 1.4%). There were no178significant differences in the total number of reads per biotype between cases and controls (all P>0.4).

179

180 Taqman validation shows good reproducibility

181 We next sought to verify validity and reproducibility of the sncRNA-seq. Taqman qPCR 182 assays for sncRNAs with high, medium and low expression were used and these showed a good 183 correlation with the RNA-seq results ($r^2 = 0.86$, Supplemental Figure 3).

184

185 sncRNAs associate with DKD, eGFR and UACR

186 Seven sncRNAs were significantly associated with prevalent DKD in the unadjusted model 187 ($P_{FDR} \le 0.05$, Table 3, Figure 1A). All identified sncRNAs were downregulated in DKD cases. The top 188 hit was snoRNA U8 (log2 fold change=-0,859, P_{FDR} =1.90x10⁻³, Figure 1B). Five of these sncRNAs 189 also showed a significant trend for lower levels in those with more advanced stages of CKD 190 ($P_{FDR} \le 0.05$, Supplemental Figure 4).

Respectively, 107 and 220 sncRNAs were significantly associated with eGFR and UACR, which are used for the DKD classification (Table 3, Supplemental Table 3, Supplemental Figures 5 and 6). The overlap between the sncRNAs associated with DKD and its components eGFR and UACR is shown in figure 1C and Table 3. snoRNA U8 overlapped between all three endpoints used and piR_019825 overlapped between eGFR and DKD. SNORD118, SNORD24, SNORD107, SNORD87 and miR-143-5p all overlapped between UACR and DKD.

In the full model respectively 7, 153 and 205 sncRNAs remained significantly associated with DKD, eGFR and UACR (Supplemental Table 4, Supplemental Figure 7; 57%; 95% and 84% overlap with the unadjusted model). U8, SNORD118, piR_019825 and miR-143-5p were significant in both the base and full models. In a sensitivity analysis, additional adjustment for use of antihypertensive medication and baseline eGFR or UACR (only for eGFR and UACR) did not have a major impact on the effect sizes but reduced the number of significant associations (r^2 >=0.92, Supplemental Figure 8).

203

204 Certain types of sncRNAs are enriched in DKD

Comparing the frequency of different types of sncRNAs identified showed that while snoRNAs represent 10% of the total small RNA transcriptome in our RNA-seq study they are the most abundant class associated with prevalent DKD (71%, OR=21.9, P= 2.4×10^{-4} , Table 2). Enrichment for snoRNAs is also seen for UACR (OR=3.8, p= 8.4×10^{-13}). Associations with miRNAs on the other hand are less frequent whilst piRNAs also seem enriched (Table 2). A similar pattern is again seen for UACR and to a lesser extend for eGFR. In the full model a largely similar picture is observed (Supplemental Table 5).

The pairwise correlation in expression between the seven sncRNAs associated with diabetic DKD was very modest (Figure 1D). The only exceptions were U8 and SNORD118, which is likely due to the fact that they are encoded in the same host gene (TMEM107) on chromosome 17. Results of these analyses for eGFR and UACR are shown in Supplemental Figure 9.

216

217 sncRNAs are tissue-enriched and correlate with plasma protein levels

In a next step, we examined the tissue expression patterns of the identified sncRNAs. We used publicly available expression data in 11 tissues or body fluids (Fig. 1E). This illustrated that some sncRNAs show tissue-enriched expression patterns. For the seven sncRNAs associated with DKD none had its highest expression in kidney tissue. piRNA-019825 was the only sncRNA that showed high expression in urine. Similar observations were made for eGFR and UACR associated sncRNAs (Supplemental Fig. 10).

224 Finally, since the function of most of the sncRNAs we found in our study is unknown we 225 compared the expression levels of the sncRNAs with expression of 1195 proteins measured in plasma 226 from the same date to identify potential targets or (co-)regulated proteins or pathways. As shown in 227 Supplemental Table 6 we found for the seven sncRNAs 31 FDR significant pairwise correlations 228 involving 24 proteins. The strongest association was observed between piR-019825 and TNF sR-1 229 (TNFRSF1A, Beta=-0.080 (-0.112 - -0.040), P_{FDR}=3.04x10⁻²). piRNA-019825 also showed the largest 230 number of correlations (n=11, Figure 2A). Interestingly, among the proteins associated with piR-231 019825 was Cystatin C, a known marker of kidney function. Next we assessed whether the 24 proteins 232 were also significantly associated with eGFR or UACR (FDR≤0.05). Six were associated with eGFR and none with UACR. Four out of the six proteins that were negatively associated with piR-019825 233 expression were also negatively associated with eGFR (all $P_{FDR} \leq 3.78 \times 10^{-11}$) (Figure 2A, Supplemental 234 235 Table 7). Two proteins were associated with miR-143-5p expression and another eleven proteins were 236 associated with snoRNA expression. Five proteins were correlated with two or more snoRNAs 237 (NAMPT, UFM1, PDGFB, CCL27 and CCL28) and two were also significantly associated with eGFR 238 (CCL27, RARRES2, Figure 2B). Pairwise correlations between the piR-019825 or snoRNA associated 239 proteins is shown in figures 2C, D

240

241 Discussion

In this study we show that circulating sncRNAs are associated with prevalent DKD in people with type 2 diabetes. Importantly these sncRNAs do not only represent miRNAs but also other classes of small non-coding RNAs. In addition, these sncRNAs correlate with proteins that function in pathways known to be involved in DKD/kidney function.

246

247 Associations between kidney function and sncRNAs

248 miRNAs

MicroRNAs are involved in the post-transcriptional regulation of gene expression and are known to be involved in crosstalk between (distant) cells and tissues [2]. As such, there is an ever growing interest to study their role in disease development and as biomarkers of disease and disease progression.

252 In our study one miRNA, miR-143-5p, was associated with both DKD and UACR. Levels of 253 this miRNA are lower in both DKD and persons with high UACR. miR-143-5p remained significant 254 in the full models, suggesting it might have biomarker potential. Previous in vitro studies showed that 255 this miRNA is associated with vascular pathology [19], an impaired glomerular filtration barrier [20] 256 and with mesangial cell proliferation and fibrosis [21, 22], miR-143-5p plasma levels associate with 257 two proteins but neither of those have a clear relationship with kidney function nor were they 258 predicted targets for miR-143-5p (miRDB, miRTarBase, MiRBase). In the full model three additional 259 microRNAs were significant, miR-455-3p, miR-122-3p and miR-193b-3p. Previously it was shown 260 that miR-455-3p was down regulated in human mesangial cells (HMC) and human proximal tubule 261 epithelial cells (HK-2) under DKD stimulating conditions [23]. Interestingly, it was also shown that 262 overexpression of this miR could alleviate the pathological changes such as renal fibrosis in a rat DN 263 model [23]. In a mouse mesangial cell line miR-455-3p improved cell proliferation, inflammation and 264 ECM accumulation induced by high glucose treatment [24]. Involvement of this miR in fibrosis in 265 other tissues like liver and lung has also been reported. A previous report indicated that miR-122, a 266 liver specific miR associated with liver injury, was reduced in patients with end stage renal disease but 267 not in CKD when compared to healthy controls [25]. miR-193b-3p was identified as a potential 268 biomarker for pre-diabetes and also for CKD after nephrectomy for renal cell carcinoma [26, 27].

In addition to the association with DKD we also found many miRNAs associated with eGFR and or UACR. A large number of which remained significant in the full models. Interestingly, of the 154 miRNAs found in the base models for eGFR and UACR only two of them were associated with both phenotypes suggesting that the associated miRNAs are specific to either defect in kidney function but not both.

274

275 piRNAs

276 PIWI-interacting RNAs are involved in silencing of transposons but they can also be involved 277 in the regulation of gene expression in a miRNA-like manner [28]. One piRNA, piRNA-019825 278 (DQ597218), was significantly associated with DKD. Previously, it was shown that this piRNA is one 279 of the most abundant piRNA species in urine and plasma [29]. In our proteomics analysis to identify 280 potential targets or pathways we found eleven proteins whose expression was correlated with the 281 levels of piR-019825 including cystatin C, a known marker for kidney function. Four of the 282 negatively associated proteins are also strongly associated with eGFR. This is in line with a putative 283 miRNA like function for piR-019825 in which lower piRNA expression would result in higher protein 284 levels, lower eGFR and increased risk of DKD. This is further corroborated by the fact that increased 285 levels of two of these proteins were previously found to increase risk of CKD or end stage renal disease (ESRD) in prospective studies in persons with diabetes (TNF sR-I (TNFRSF1A), NBL1 286 287 (DAN) [30-33]. Whereas the other negatively associated proteins we found associated with this 288 piRNA (CST3, sCXCL16, CFD, PLA2G2A) have almost all also been implicated previously in kidney 289 dysfunction [34-36]. Interestingly, we also find various other piRNAs associated with either eGFR and 290 or UACR (10-14%). Most of which remained significant in the full models. Suggesting that they may 291 be useful early markers of DKD. Of note, eGFR-associated piRNAs often show their highest 292 expression in urine, whereas UACR associated piRNAs show low expression in urine, but often high 293 levels in tissues like pancreas, liver and colon.

294

295 snoRNAs

296 Small Nucleolar RNAs (snoRNA) are predominantly localized to the nucleolus where they 297 have a function in rRNA biogenesis, structure and activity [37]. There are two major types of 298 snoRNAs containing either box C/D or box H/ACA motifs. In our study we only detected box C/D 299 snoRNAs associated with DKD. Box C/D snoRNAs are involved in 2'-O-methylation of specific 300 sequences in target RNA sequences, mainly rRNA, thereby affecting RNA structure, stability and 301 interactions. In addition, other functions have been ascribed to the snoRNAs such as mRNA splicing 302 and editing. SnoRNA derived fragments have also been described and it has been speculated that they 303 exert piRNA or miRNA like functions [38].

304 Although snoRNAs represent only ten percent of the total circulating sncRNA transcriptome in our 305 study they represent seventy-one percent of the sncRNAs found associated with DKD suggesting that 306 snoRNAs may function as early biomarkers of DKD. SnoRNA U8 was associated with all three 307 phenotypes but has not been linked to kidney function previously. SnoRNAs SNORD118, SNORD24, 308 SNORD107 and SNORD87 where associated with DKD and UACR but not eGFR. SnoRNAs U8 and 309 SNORD118 both remained significant in the full models. SNORD87 and SNORD107 associate with 310 the same set of proteins, including UFM1, NAMPT, PDGFB, and the two chemokines CCL27 and 311 CCL28, which bind to the same receptor (CCR10). A recent report by Chen et al. showed that post-312 transcriptional stabilization of the CCL28 mRNA by N6-methyladenosine (m6A) modification

313 increases protein levels of this chemokine and reduces kidney damage after ischemia reperfusion 314 injury [39]. Given the known role of snoRNAs in post-transcriptional RNA modification and 315 stabilization via 2'-O-methylation this might provide a putative mechanism and explanation for the 316 observed snoRNA-protein associations. The other proteins associated with these snoRNAs (UFM1, 317 NAMPT, PDGFB) have also been implicated in kidney function previously [40-43]. Further studies 318 are needed to investigate the role of these snoRNAs in DKD. In addition to the snoRNAs described 319 above various other snoRNAs are associated with eGFR and UACR (13-31% of total number of 320 significant sncRNA). Almost all remained significant in the full models. At present there are no other 321 studies that have investigated the role of snoRNAs in diabetic DKD.

322

323 Members of other sncRNA classes

Although other classes of sncRNAs, such as Y_RNA derived fragments, tRNA fragments (tRF), IncRNA fragments and snRNAs represent roughly twenty percent of all circulating sncRNA detected we did not find any significant associations with DKD. We did find a small number of associations with eGFR and UACR though.

328

329 Strengths and limitations

Our study has several strengths. It is one of the largest circulating sncRNA profiling studies studying the role of circulating sncRNAs in DKD. This improves power and reduces the chance of false positives. In addition, it uses untargeted RNA sequencing allowing not only the study of miRNAs but also several other classes of sncRNA showing that especially these other types of sncRNAs associated with DKD and its components eGFR and UACR. The use of early, mainly mild cases of DKD facilitates the identification of early markers of disease and may help to introduce early interventions aiming to preserve kidney function in those at risk.

A limitation of our study is the use of a total RNA isolation procedure and as such we were not able to investigate if the sncRNAs are carried by extracellular vesicles or are associated with carriers such as HDL and Ago-2 [2]. The use of plasma for RNA isolation is another limitation. Although from a biomarker perspective this is not a limitation, from a functional perspective the role of the sncRNAs we identified needs to be established in the relevant cells and tissues. Another limitation of our study is its cross-sectional, observational design. As such we cannot exclude that (part of) the observed changes and associations are a reflection of the reduced kidney function in the participants.

344

In conclusion, in this study we have shown that several circulating sncRNAs are associated with DKD.

346 Interestingly, only a relatively small fraction belong to the well-studied microRNAs. This highlights

347 the potential involvement of other classes of sncRNAs, such as snoRNAs and piRNAs, that have so far

348 not been investigated in relation to kidney function before. Future prospective and functional studies

- 349 are needed to establish the role of these novel circulating sncRNAs in subjects with diabetes and
- 350 chronic kidney disease.

351

353 Statements and Declarations

354 Conflict of Interest

- 355 The authors declare that they have no conflict of interest.
- 356

357 Acknowledgements

358 We would like to thank all staff and participants of the Hoorn Diabetes Care System for their support

- and participation.
- 360

361 Funding

362 This work was supported by a diabetes breakthrough grant from the Dutch Diabetes Research 363 Foundation and ZonMw (grant number 459001015) and a grant from the EFSD/Boehringer Ingelheim 364 European Research Programme on "Multi-System Challenges in Diabetes" 2021. The proteomic 365 analyses were funded by a grant from the Innovative Medicines Initiative 2 Joint Undertaking, under 366 grant agreement no. 115881 (RHAPSODY). This Joint Undertaking receives support from the 367 European Union's Horizon 2020 research and innovation program and EFPIA and is supported by the 368 Swiss State Secretariat for Education, Research and Innovation (SERI), under contract no. 16.0097. 369 The study sponsors/funders were not involved in the design of the study; the collection, analysis, and 370 interpretation of data; writing the report; and did not impose any restrictions regarding the publication 371 of the report.

372

373 Competing interests

- 374 The authors have no relevant financial or non-financial interests to disclose.
- 375

376 Author Contributions

LMtH, JWJB and RCS designed the study. JAdK and SJC isolated RNA and prepared the samples for RNAseq. MTB and JWJB were responsible for phenotypic data acquisition and preparation. LMtH, GAB and RCS prepared, analyzed and interpreted the data. LMtH and RCS wrote the first draft of the manuscript. RB contributed to the critical interpretation of the results. LMtH and RCS are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors critically read and revised the manuscript and approved the final version of the manuscript.

384

385 Ethics approval

386 This study was performed in line with the principles of the Declaration of Helsinki. The study has

387 been approved by the ethics committee of the Amsterdam University Medical Center, location VUmc

388 (approval number 2007/57; NL14692.029.07).

390 Consent to participate

391 All participants provided written informed consent prior to participating in this study.

392

393 Data availability

- 394 The datasets generated during and/or analyzed during the current study are not publicly available due
- restrictions in the informed consent but are available from the corresponding author on reasonable
- 396 request.

397

398 References

Persson F, Rossing P (2018) Diagnosis of diabetic kidney disease: state of the art and future
perspective. Kidney Int Suppl (2011) 8(1): 2-7. 10.1016/j.kisu.2017.10.003
van Zonneveld AJ, Zhao Q, Rotmans JI, Bijkerk R (2023) Circulating non-coding RNAs in
chronic kidney disease and its complications. Nat Rev Nephrol 19(9): 573-586. 10.1038/s41581-023-

403 00725-w

404 [3] Loganathan TS, Sulaiman SA, Abdul Murad NA, et al. (2020) Interactions Among Non 405 Coding RNAs in Diabetic Nephropathy. Front Pharmacol 11: 191. 10.3389/fphar.2020.00191

- 406 [4] Gholaminejad A, Abdul Tehrani H, Gholami Fesharaki M (2018) Identification of candidate
- 407 microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies. J Nephrol.
 408 10.1007/s40620-018-0511-5
 409 [5] Assmann TS, Recamonde-Mendoza M, de Souza BM, Bauer AC, Crispim D (2018)
- MicroRNAs and diabetic kidney disease: Systematic review and bioinformatic analysis. Mol Cell
 Endocrinol 477: 90-102. 10.1016/j.mce.2018.06.005
- 412 [6] Freedman JE, Gerstein M, Mick E, et al. (2016) Diverse human extracellular RNAs are widely
 413 detected in human plasma. Nat Commun 7: 11106. 10.1038/ncomms11106
- 414 [7] van der Heijden AA, Rauh SP, Dekker JM, et al. (2017) The Hoorn Diabetes Care System

(DCS) cohort. A prospective cohort of persons with type 2 diabetes treated in primary care in the
 Netherlands. BMJ Open 7(5): e015599. 10.1136/bmjopen-2016-015599

417 [8] KDIGO (2013) Kidney Disease: Improving Global Outcomes (KDIGO). CKD work group.
418 KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney

419 Disease. . Kidney Int 3: 1-150

- 420 [9] Rozowsky J, Kitchen RR, Park JJ, et al. (2019) exceRpt: A Comprehensive Analytic Platform
 421 for Extracellular RNA Profiling. Cell Syst 8(4): 352-357.e353. 10.1016/j.cels.2019.03.004
- 422 [10] Griffiths-Jones S (2004) The microRNA Registry. Nucleic Acids Res 32(Database issue):
 423 D109-111. 10.1093/nar/gkh023
- 424 [11] Sai Lakshmi S, Agrawal S (2008) piRNABank: a web resource on classified and clustered
- 425 Piwi-interacting RNAs. Nucleic Acids Res 36(Database issue): D173-177. 10.1093/nar/gkm696
- 426 [12] Harrow J, Frankish A, Gonzalez JM, et al. (2012) GENCODE: the reference human genome
 427 annotation for The ENCODE Project. Genome Res 22(9): 1760-1774. 10.1101/gr.135350.111
- 428 [13] Glažar P, Papavasileiou P, Rajewsky N (2014) circBase: a database for circular RNAs. Rna
 429 20(11): 1666-1670. 10.1261/rna.043687.113
- 430 [14] Chan PP, Lowe TM (2009) GtRNAdb: a database of transfer RNA genes detected in genomic
 431 sequence. Nucleic Acids Res 37(Database issue): D93-97. 10.1093/nar/gkn787
- 432 [15] ThermoFisherScientific (2016) A technical guide to identifying miRNA normalizers using
- 433 TaqMan Advanced miRNA Assays. Available from <u>https://assets.thermofisher.com/TFS-</u>
- 434 <u>Assets/GSD/Reference-Materials/identifying-mirna-normalizers-white-paper.pdf</u>
- 435 [16] Barrett T, Wilhite SE, Ledoux P, et al. (2012) NCBI GEO: archive for functional genomics
- 436 data sets—update. Nucleic Acids Research 41(D1): D991-D995. 10.1093/nar/gks1193
- 437 [17] Slieker RC, Donnelly LA, Fitipaldi H, et al. (2021) Distinct Molecular Signatures of Clinical
 438 Clusters in People with Type 2 Diabetes: an IMIRHAPSODY Study. Diabetes 70(11): 2683-2693.
- 439 10.2337/db20-1281

440 Robinson MD, McCarthy DJ, Smyth GK (2009) edgeR: a Bioconductor package for [18] 441 differential expression analysis of digital gene expression data. Bioinformatics 26(1): 139-140. 442 10.1093/bioinformatics/btp616 443 Taïbi F, Metzinger-Le Meuth V, M'Baya-Moutoula E, et al. (2014) Possible involvement of [19] 444 microRNAs in vascular damage in experimental chronic kidney disease. Biochim Biophys Acta 445 1842(1): 88-98. 10.1016/j.bbadis.2013.10.005 446 Müller-Deile J, Gellrich F, Schenk H, et al. (2016) Overexpression of TGF- β Inducible [20] 447 microRNA-143 in Zebrafish Leads to Impairment of the Glomerular Filtration Barrier by Targeting 448 Proteoglycans. Cell Physiol Biochem 40(5): 819-830. 10.1159/000453142 449 Bai S, Xiong X, Tang B, et al. (2020) Exosomal circ_DLGAP4 promotes diabetic kidney [21] 450 disease progression by sponging miR-143 and targeting ERBB3/NF-KB/MMP-2 axis. Cell Death Dis 451 11(11): 1008. 10.1038/s41419-020-03169-3 452 Ge X, Xi L, Wang O, et al. (2020) Circular RNA Circ 0000064 promotes the proliferation and [22] 453 fibrosis of mesangial cells via miR-143 in diabetic nephropathy. Gene 758: 144952. 454 10.1016/j.gene.2020.144952 455 [23] Wu J, Liu J, Ding Y, et al. (2018) MiR-455-3p suppresses renal fibrosis through repression of 456 ROCK2 expression in diabetic nephropathy. Biochem Biophys Res Commun 503(2): 977-983. 457 10.1016/j.bbrc.2018.06.105 458 Zhu XJ, Gong Z, Li SJ, Jia HP, Li DL (2019) Long non-coding RNA Hottip modulates high-[24] 459 glucose-induced inflammation and ECM accumulation through miR-455-3p/WNT2B in mouse 460 mesangial cells. Int J Clin Exp Pathol 12(7): 2435-2445 461 [25] Rivoli L, Vliegenthart AD, de Potter CM, et al. (2017) The effect of renal dysfunction and 462 haemodialysis on circulating liver specific miR-122. Br J Clin Pharmacol 83(3): 584-592. 463 10.1111/bcp.13136 464 Mollet IG, Macedo MP (2023) Pre-Diabetes-Linked miRNA miR-193b-3p Targets [26] 465 PPARGC1A, Disrupts Metabolic Gene Expression Profile and Increases Lipid Accumulation in 466 Hepatocytes: Relevance for MAFLD. Int J Mol Sci 24(4). 10.3390/ijms24043875 467 [27] Trevisani F, Ghidini M, Larcher A, et al. (2016) MicroRNA 193b-3p as a predictive biomarker 468 of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. Br J 469 Cancer 115(11): 1343-1350. 10.1038/bjc.2016.329 470 Ozata DM, Gainetdinov I, Zoch A, O'Carroll D, Zamore PD (2019) PIWI-interacting RNAs: [28] 471 small RNAs with big functions. Nat Rev Genet 20(2): 89-108. 10.1038/s41576-018-0073-3 472 [29] El-Mogy M, Lam B, Haj-Ahmad TA, et al. (2018) Diversity and signature of small RNA in 473 different bodily fluids using next generation sequencing. BMC Genomics 19(1): 408. 10.1186/s12864-474 018-4785-8 475 Gohda T, Niewczas MA, Ficociello LH, et al. (2012) Circulating TNF receptors 1 and 2 [30] 476 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23(3): 516-524. 10.1681/asn.2011060628 477 [31] Niewczas MA, Gohda T, Skupien J, et al. (2012) Circulating TNF receptors 1 and 2 predict 478 ESRD in type 2 diabetes. J Am Soc Nephrol 23(3): 507-515. 10.1681/asn.2011060627 479 Kobayashi H, Looker HC, Satake E, et al. (2022) Neuroblastoma suppressor of tumorigenicity [32] 480 1 is a circulating protein associated with progression to end-stage kidney disease in diabetes. Sci 481 Transl Med 14(657): eabj2109. 10.1126/scitranslmed.abj2109 482 [33] Niewczas MA, Pavkov ME, Skupien J, et al. (2019) A signature of circulating inflammatory 483 proteins and development of end-stage renal disease in diabetes. Nat Med 25(5): 805-813. 484 10.1038/s41591-019-0415-5 485 [34] Christensson A, Ash JA, DeLisle RK, et al. (2018) The Impact of the Glomerular Filtration 486 Rate on the Human Plasma Proteome. Proteomics Clin Appl 12(3): e1700067. 487 10.1002/prca.201700067 488 [35] Jalal D, Sanford B, Renner B, et al. (2021) Detection of pro angiogenic and inflammatory 489 biomarkers in patients with CKD. Sci Rep 11(1): 8786. 10.1038/s41598-021-87710-0 490 Ngo D, Wen D, Gao Y, et al. (2020) Circulating testican-2 is a podocyte-derived marker of [36] 491 kidney health. Proc Natl Acad Sci U S A 117(40): 25026-25035. 10.1073/pnas.2009606117 492 Deogharia M, Majumder M (2018) Guide snoRNAs: Drivers or Passengers in Human [37] 493 Disease? Biology (Basel) 8(1). 10.3390/biology8010001

- 494 [38] Bergeron D, Fafard-Couture É, Scott MS (2020) Small nucleolar RNAs: continuing
- 495 identification of novel members and increasing diversity of their molecular mechanisms of action.
 496 Biochem Soc Trans 48(2): 645-656. 10.1042/bst20191046
- 497 [39] Chen J, Xu C, Yang K, et al. (2023) Inhibition of ALKBH5 attenuates I/R-induced renal
- injury in male mice by promoting Ccl28 m6A modification and increasing Treg recruitment. Nat
 Commun 14(1): 1161. 10.1038/s41467-023-36747-y
- 500 [40] Ostendorf T, Boor P, van Roeyen CR, Floege J (2014) Platelet-derived growth factors
- 501 (PDGFs) in glomerular and tubulointerstitial fibrosis. Kidney Int Suppl (2011) 4(1): 65-69.
- 502 10.1038/kisup.2014.12
- 503 [41] Li H, Li M, Liu C, et al. (2023) Causal effects of systemic inflammatory regulators on chronic
- kidney diseases and renal function: a bidirectional Mendelian randomization study. Front Immunol 14:
 1229636. 10.3389/fimmu.2023.1229636
- 506 [42] Hu X, Zhang H, Zhuang L, et al. (2020) Ubiquitin-Fold Modifier-1 Participates in the Diabetic
- 507 Inflammatory Response by Regulating NF-κB p65 Nuclear Translocation and the Ubiquitination and
- 508 Degradation of I κ B α . Drug Des Devel Ther 14: 795-810. 10.2147/dddt.S238695
- 509 [43] Muraoka H, Hasegawa K, Sakamaki Y, et al. (2019) Role of Nampt-Sirt6 Axis in Renal
- 510 Proximal Tubules in Extracellular Matrix Deposition in Diabetic Nephropathy. Cell Rep 27(1): 199-
- 511 212.e195. 10.1016/j.celrep.2019.03.024
- 512

513

	all	No DKD	DKD						
n	475	406	69						
Gender (%Female)	45	46	42						
Age (years)	61.4 ± 9.1	61.0 ± 8.8	63.8 ± 10.1*						
BMI (Kg/m ²)	30.7 ± 6.0	30.3 ± 5.6	32.7 ± 7.3*						
Age-at-Diagnosis (years)	59.3 ± 9.0	58.8 ± 8.7	61.8 ± 9.8*						
Diabetes duration (years)	2.2 ± 1.1	2.2 ± 1.1	2.0 ± 1.1						
Fasting glucose (mmol/L)	8.0 ± 1.6	8.0 ± 1.7	8.1 ± 1.4						
HbA1c (mmol/mol)	46 (42, 51)	46 (42, 51)	46 (43, 54)						
HDL (mmol/L)	1.19 ± 0.32	1.20 ± 0.33	1.11 ± 0.25						
eGFR (ml/min/1,73 m ²)	84 ± 16	87 ± 13	$70 \pm 22*$						
$eGFR \leq 60$ (%)	34 (7)	0	34 (50)						
Urine Albumin-to-	0.48 (0.20, 1.00)	0.41 (0.18, 0.79)	3.99 (0.79, 10.5)*						
Creatinine ratio (mg/mmol)									
Albuminuria (%)	43 (9)	0	43 (62)						
Chronic Kidney Disease	69 (15)	0	69 (100)						
(%))									
Diastolic blood pressure	78 ± 9	78 ± 9	79 ± 10						
(mm Hg)									
Systolic blood pressure	139 ± 18	139 ± 18	142 ± 20						
(mm Hg)									
Smoking	92/130/250	76/107/220	16/23/30						
(current/ever/never)									
Medication use									
Metformin (%)	340 (72)	287 (71)	53 (77)						
SU (%)	130 (27)	105 (26)	25 (36)						
Other glucose-lowering (%)	13 (3)	12 (3)	1(1)						
Antihypertensive	319 (67)	260 (64)	59 (86)*						
medication (%)									
Lipid lowering medication	320 (67)	271 (67)	49 (71)						
(%)									

515 Table 1. Clinical characteristics of the study population.

516

Data are mean \pm SD, n (%) or median (IQR). All measures taken at the time of blood sampling.

517 * $P \leq 0.05$ versus those without DKD.

	Total # of sncRNA detected			DKD				eGFR				UACR			
	n	%		n	%	p*		n	%	p*		n	%	p*	
Total # sncRNAs	938	100		7				107				220			
miRNA	602	64		1	14	0.011		63	59	0.29		93	42	4.5x10 ⁻⁹	
snoRNA	96	10		5	71	2.2x10 ⁻⁴		14	13	0.40		67	31	8.4x10 ⁻¹³	
lncRNA	93	10						13	12	0.50		20	9	0.80	
piRNA	45	5		1	14	0.30		11	10	0.037		23	11	4.0×10^{-3}	
Y_RNA fragments	33	4										1	0.5	0.013	
others	26	3										6	3	1.00	
tRNA fragments	24	3						4	4	0.52		1	0.5	0.067	
snRNA	12	1						1	1	1.00		6	3	0.13	
scaRNA	7	1						1	1	0.58		3	1	0.41	

519 Table 2. Frequency of different types of sncRNAs associated with the three endpoints.

* P-value for comparison against the distribution of all sncRNAs detected.

520 521

sncRNA	Prevalen	t DKD	eGFR		UACR		
	LogFC	P _{FDR}	logFC	P _{FDR}	logFC	P _{FDR}	
U8	-0,859	1,90x10 ⁻⁰³	0,012	$2,79 \times 10^{-02}$	-0,724	$6,74 \times 10^{-03}$	
SNORD118	-0,861	1,90x10 ⁻⁰³	0,009	8,94x10 ⁻⁰²	-0,858	$1,73 \times 10^{-03}$	
miR-143-5p	-0,429	$4,01 \times 10^{-02}$	0,000	9,86x10 ⁻⁰¹	-0,376	$3,30 \times 10^{-02}$	
SNORD24	-0,785	$4,01 \times 10^{-02}$	0,011	$6,42 \times 10^{-02}$	-0,919	$1,73 \times 10^{-03}$	
piR_019825 DQ597218	-0,485	4,91x10 ⁻⁰²	0,012	$3,04 \times 10^{-03}$	-0,129	5,71x10 ⁻⁰¹	
SNORD107	-1,194	4,91x10 ⁻⁰²	0,013	1,43x10 ⁻⁰¹	-2,214	1,58x10 ⁻⁰⁵	
SNORD87	-1,129	$4,91 \times 10^{-02}$	0,012	$2,17 \times 10^{-01}$	-2,253	1,18x10 ⁻⁰⁵	

523 Table 3. Overview of seven sncRNAs associated with prevalent DKD

524 LogFC is the log2 of the fold change. P_{FDR} represents the P value after correction for multiple hypothesis testing using the Benjamini-Hochberg procedure.



525 Figure 1. sncRNAs significantly associated with DKD.

526

527 Panel A. Volcano plot showing the association between sncRNAs and DKD in the base model. sncRNAs in blue are 528 significantly lower is cases with DKD after multiple hypothesis testing (FDR≤0.05). logFC is the Log2 of the fold change 529 between cases and controls. Panel B. U8 levels in those with or without DKD. CPM = counts per million reads. Panel C. 530 Overlap between sncRNAs significantly associated with DKD, eGFR or UACR in the base model. Panel D. Pairwise 531 correlations for the seven sncRNAs associated with DKD. Colors represent Spearman's rho. Panel E. Expression pattern for 532 sncRNAs associated with DKD in publicly available datasets for 11 tissues of interest. Colors represent the Z-scaled 533 expression of a sncRNA where blue indicates relative high expression and red relative low expression.

534

536 Figure 2. sncRNAs associated proteins.



537

538

539 Overview of the proteins that associate with sncRNA expression levels in plasma from persons with T2D. sncRNAs and

540 proteins in green are also significantly associated with eGFR and those in blue are associated with UACR ($P_{FDR} \le 0.05$). Blue

541 line and text indicate a negative association and a red line and text indicates a positive association. Panel A. piR-019825

 $542 \qquad \text{associated proteins (} P_{FDR} \leq 0.05\text{)}. \text{ Panel B. snoRNA associated proteins (} P_{FDR} \leq 0.05\text{)}. \text{ Panel C. Pairwise correlations between}$

the 11 piR-019825 associated proteins. Panel D. Pairwise correlations between the 11 snoRNA associated proteins.

544